Study guide

Cervical screening and cervical cancer

AMC CAT MCQ Examination AMC Part 1

Track your progress as you read

Finished sections get a check mark.

1 Acute Coronary Syndromes & ECG Localization

ACS recognition and ECG localisation Reperfusion and infarction complications

2 Heart Failure, Cardiogenic Shock & Cardiac Arrhythmias

Heart failure assessment and treatment Arrhythmias and conduction emergencies

3 Systemic Hypertension & Peripheral Vascular Disease

Blood pressure and cardiovascular risk Secondary hypertension and arterial disease

4 Valvular Heart Disease, Infective Endocarditis & Pericarditis

Aortic and mitral valve disease Endocarditis and pericardial emergencies

5 Asthma & COPD Acute Flares and Maintenance

Asthma and COPD diagnosis and maintenance Acute asthma and COPD exacerbations

6 Pneumonia, pleural disease and respiratory failure

Pneumonia and infected pleural collections Pulmonary embolism, effusions and pneumothorax Respiratory failure, ARDS and sepsis

7 GI bleeding, bowel inflammation and malabsorption

GI bleeding assessment and resuscitation Varices, ulcers, reflux and lower GI bleeding IBD patterns and severe colitis assessment IBD treatment, coeliac disease and IBS

8 Chronic Liver Disease, Cirrhosis Complications & Acute Hepatitis

Cirrhosis diagnosis and prognosis Decompensation, viral hepatitis and surveillance

9 Diabetes, thyroid and adrenal disease

Diabetes diagnosis and ongoing care DKA, HHS and complication monitoring Thyroid disease assessment Thyroid emergencies and adrenal disease

10 Acute Kidney Injury, Chronic Kidney Disease & Fluid/Electrolyte Emergencies

AKI and chronic kidney disease Potassium and sodium emergencies

11 Anaemias, Inflammatory Arthropathies & Geriatric Comprehensive Assessment

Anaemia, bruising and blood disorders Arthritis, autoimmune disease and geriatric care

12 Evaluation of the Acute Abdomen, Peritonitis & Appendicitis

Abdominal pain, peritonitis and resuscitation Appendicitis diagnosis and treatment Perforation and mesenteric ischaemia

13 Small and Large Bowel Obstruction & Colorectal Surgical Pathology

Small bowel obstruction Colonic obstruction, volvulus and cancer recognition Colorectal care, diverticulitis and anorectal symptoms

14 Gallbladder Disease, Biliary Tract Infections & Acute Pancreatitis

Gallstones and biliary obstruction Cholangitis and pancreatitis diagnosis Pancreatitis severity and treatment

15 Advanced Trauma Life Support, Primary Survey & Life-Threatening Thoracic Injuries

Trauma primary survey and adjuncts Chest trauma and immediate threats

16 Traumatic Brain Injury, Intracranial Haemorrhage & Spinal Cord Clearance

Head injury, imaging and haemorrhage Herniation and spinal cord injury

17 Major Fractures, Joint Dislocations & Acute Compartment Syndrome

Fracture assessment and open injuries Compartment syndrome, dislocations and pelvic injury

18 Thermal Burns, Haemorrhagic Shock Resuscitation & Surgical Wound Care

Burn assessment and fluid resuscitation Bleeding shock, wound care and tetanus

19 Aortic Aneurysms & Acute Arterial Limb Ischaemia

Aneurysm recognition and planned care Ruptured aneurysm and acute limb ischaemia

20 Urological Emergencies, Testicular Torsion & Haematuria Investigation

Retention, stones and obstructed infection Scrotal pain and haematuria

21 Preoperative Risk Stratification & Postoperative Surgical Complications

Preoperative assessment and medicines Postoperative complications and prevention

22 Early Pregnancy Bleeding, Ectopic Pregnancy & Antenatal Screening

Miscarriage and ectopic pregnancy Antenatal screening and early-pregnancy comparisons

23 Hypertensive Disorders of Pregnancy & Medical Complications in Pregnancy

Pregnancy hypertension and preeclampsia Eclampsia, HELLP and antepartum bleeding

24 Intrapartum Monitoring, Postpartum Haemorrhage & Obstetric Emergencies

Labour physiology and CTG assessment CTG response and postpartum haemorrhage Obstetric emergencies and preterm birth

25 Abnormal Uterine Bleeding, Pelvic Pain & Endometriosis

Abnormal bleeding and structural causes Endometrial sampling and endometriosis PCOS diagnosis and long-term care

26 Contraception, Emergency Contraception & Pregnancy Termination

Contraceptive choice and missed pills Emergency contraception and abortion

27 Australian Cervical Screening Program & Gynaecological Malignancies

Cervical screening and cervical cancer Endometrial and ovarian cancer

28 Neonatal Resuscitation, Congenital Conditions & Neonatal Jaundice

Newborn resuscitation, Apgar and cyanosis Neonatal jaundice assessment Jaundice treatment and congenital screening

29 Developmental Milestones, Growth Charts & Failure to Thrive

Developmental milestones Regression, autism and support Faltering growth and developmental comparisons

30 The Limping Child, Septic Arthritis vs Transient Synovitis & Paediatric Hip Conditions

Limp assessment and septic-joint risk Joint-infection management and Perthes disease SUFE and paediatric hip comparisons

31 Croup, Bronchiolitis, Paediatric Asthma & Anaphylaxis

Croup Bronchiolitis Paediatric asthma Paediatric anaphylaxis

32 Evaluation of the Febrile Child, Sepsis & Meningococcal Disease

Febrile neonates and young infants Meningococcal disease and paediatric sepsis Bacterial meningitis and CSF interpretation Kawasaki disease and follow-up

33 Paediatric Surgical Abdomen, Dehydration & Child Protection / Non-Accidental Injury

Pyloric stenosis Intussusception and dehydration Child protection and injury assessment

34 The Mental State Examination & Suicide Risk Stratification

Mental state examination and psychotic symptoms Suicide formulation and mental health law

35 Major Depressive Disorder, Bipolar Affective Disorder & Mood Stabilisers

Depression assessment and treatment Serotonin toxicity and bipolar presentations Mood stabilisers and ECT

36 Generalised Anxiety, Panic Disorder, PTSD & Obsessive-Compulsive Disorder

Anxiety, panic and agoraphobia OCD and trauma-related disorders

37 Schizophrenia, Acute Psychosis & Antipsychotic Management

Psychosis assessment and antipsychotics Clozapine and severe adverse effects

38 Substance Use Disorders & Acute Withdrawal Syndromes

Substance disorders and alcohol withdrawal Wernicke disease, opioids and stimulants

39 Delirium vs Dementia, Perinatal Mood Disorders & Paediatric Psychiatry

Delirium and dementia assessment Cognitive behaviour, perinatal and childhood psychiatry

40 Medicare, PBS, AHPRA & Good Medical Practice Framework

Australian health services and Medicare PBS access and professional registration Professional boundaries and notifications

41 Informed Consent (Rogers v Whitaker), Mental Capacity & Involuntary Treatment

Consent, material risks and young people Capacity, refusal and substitute decisions

42 Patient Privacy, Confidentiality Exceptions & Mandatory Notifications

Privacy, disclosure and child reporting Driving fitness and threat disclosure

43 First Nations health and preventive care

First Nations health, determinants and cultural safety Community care, Item 715 and CTG medicines Immunisation and cancer screening entry points Screening pathways and primary CVD prevention

44 Epidemiological Metrics, Clinical Study Designs & Notifiable Communicable Diseases

Epidemiology, calculations, bias and surveillance

45 Neurological presentations

Stroke, TIA and focal weakness Headache, facial pain and vertigo Seizures, collapse and altered consciousness Numbness, movement disorders and generalised weakness

46 Musculoskeletal pain

Back, neck, bone and soft tissue pain

47 Eye presentations

Altered vision and retinal disease Red eye, ocular injury and discharge

48 Ear, nose, throat and oral health

Ear pain, hearing loss and tinnitus Nasal problems, neck lumps, hoarseness and dysphagia Toothache, mouth symptoms, dry mouth and halitosis

49 Skin, hair and nails

Rash, itch, infection and skin ulcers Skin lesions, hair loss and nail abnormalities

50 Breast health and feeding

Breast lumps, discharge and breastfeeding problems

51 Sexual and reproductive presentations

Genital symptoms, discharge and pelvic infection Menopause, prolapse and urinary symptoms Infertility and sexual dysfunction

52 Palliative care and carers

The dying patient, symptoms and carers

53 Eating disorders and personality care

Eating disorders, obesity and weight change Personality difficulties, self-harm and complex care

54 Sleep presentations

Insomnia, snoring and daytime sleepiness

55 Poisoning, resuscitation and environmental emergencies

Poisoning, toxidromes and antidote decisions Cardiopulmonary arrest, choking and emergency help Bites, stings, heat, cold and drowning

56 Communication, rights and professional practice

Communication, handover, errors and complaints Healthcare rights, inclusive care and equitable access Certificates, deaths, CPD and supervision Telehealth, images, prescribing and doctors' health

57 Genetics, research and donation

Genetic testing, research and organ donation

58 Travel, fever and outbreaks

Fever, travellers and outbreak response

Cervical screening and cervical cancer

Key Takeaways Explain This Topic AI

Routine cervical screening applies from age 25 to 74 in eligible people with a cervix.

HPV16/18 detection generally requires colposcopic assessment.

Bleeding symptoms require diagnostic assessment rather than routine screening alone.

Last updated: October 2026

Australian Cervical Screening Program & Gynaecological Malignancies

Gynaecological oncology encompasses the prevention, early detection, and multidisciplinary treatment of malignancies of the cervix, endometrium, and ovary. In Australia, population-based screening has transformed cervical cancer epidemiology, while transvaginal ultrasound triage protocols and biomarker stratification govern the management of postmenopausal bleeding and suspicious pelvic masses.

The Australian National Cervical Screening Program (NCSP)

In December 2017, Australia transitioned from 2-yearly conventional Papanicolaou cytology to 5-yearly primary human papillomavirus (HPV) nucleic acid testing , a change that significantly improved sensitivity for detecting high-grade cervical intraepithelial neoplasia (CIN 2/3) and adenocarcinoma in situ (AIS).

Target Population & Collection Modalities

Eligible Cohort : Asymptomatic individuals with a cervix aged 25 to 74 years (commencing at age 25, exit screening between ages 70 and 74 if prior tests were negative).

Clinician-Collected Sample : Performed via speculum examination using a cervical broom or brush to sample the transformation zone (the squamocolumnar junction), rinsed into liquid-based cytology (LBC) transport medium (ThinPrep).

Self-Collected Vaginal Swab : Available since July 2022 to all eligible screening participants as an empowered, universal choice. Performed using a dry flocked swab inserted into the mid-vagina. Polymerase chain reaction (PCR) assays demonstrate equivalent clinical sensitivity and specificity for oncogenic HPV detection compared to clinician collection. If oncogenic HPV (non-16/18) is detected on a self-collected sample, the patient must attend for a speculum examination to obtain cervical cells for reflex LBC before clinical management is determined.

Triage Algorithm and Referral Guidelines

Low Risk (Oncogenic HPV Not Detected) :

Return to routine screening in 5 years .

High Risk (Oncogenic HPV Types 16 and/or 18 Detected) :

HPV 16 and 18 are responsible for > 70 % > 70\% > 70% of cervical cancers and carry the highest immediate risk of high-grade disease.

Mandatory direct referral for colposcopy , regardless of the reflex LBC result (even if LBC is completely normal/negative).

Intermediate Risk (Oncogenic HPV Non-16/18 Detected) :

Includes oncogenic types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. The laboratory automatically performs reflex liquid-based cytology (LBC) on the collected sample:

LBC Negative or Low-Grade Squamous Intraepithelial Lesion (p-LSIL / LSIL) : Advise the patient to have a repeat HPV test in 12 months in general practice.

Twelve-month follow-up: HPV negative generally returns to routine five-year screening. Persistent non-16/18 HPV with negative/low-grade LBC usually has another twelve-month follow-up; First Nations participants, those at least fifty and substantially underscreened patients can need colposcopy at this point. Persistent HPV at twenty-four months warrants colposcopy. Use the current history-specific NCSP pathway.

LBC High-Grade Squamous Intraepithelial Lesion (p-HSIL / HSIL) , Atypical Squamous Cells Cannot Exclude HSIL (ASC-H) , Atypical Glandular/Endocervical Cells , or Suspicion of Microinvasive/Invasive Carcinoma : Immediate referral for colposcopy .

Symptomatic Women Exempt from Screening Pathways

Symptoms require diagnostic assessment, including examination and an appropriate co-test rather than routine self-screening. Persistent/recurrent postcoital bleeding, a visible lesion or abnormal examination needs referral. A single episode with a normal cervix and negative co-test does not always require gynaecological referral. Persistent unexplained discharge or postmenopausal bleeding requires its own assessment regardless of a recent screening result.

  • Cervical Carcinoma
  • Epidemiology & Histopathology

Persistent high-risk oncogenic HPV infection is the necessary cause of > 99 % > 99\% > 99% of cervical cancers. Viral oncoproteins E6 (which binds and accelerates the degradation of the tumour suppressor protein p53) and E7 (which binds and inactivates the retinoblastoma tumour suppressor protein pRb) drive unchecked cell cycle progression and genomic instability.

Squamous Cell Carcinoma (SCC) : Accounts for 70% to 80% of cases, arising at the transformation zone.

Adenocarcinoma : Accounts for 20% to 25% of cases, arising from endocervical columnar epithelium (disproportionately associated with HPV 18). Its relative incidence has increased because cytology is less sensitive at sampling the endocervical canal.

Clinical Presentation

Early-stage carcinoma is frequently asymptomatic, underscoring the role of the NCSP.

The cardinal presenting symptom is postcoital bleeding (PCB) , followed by intermenstrual bleeding, postmenopausal bleeding, and offensive serosanguinous vaginal discharge.

Advanced lesions produce pelvic pain radiating to the sacrum, sciatic nerve pain, lower extremity oedema (from iliac venous compression or lymphatic obstruction), and oliguria/uraemia from bilateral ureteric obstruction.

FIGO Staging and Management

Staging is clinical and pathological, incorporating cross-sectional imaging (pelvic MRI and whole-body PET-CT):

Stage I : Confined strictly to the cervix uteri (IA: microscopic depth < 5 mm < 5\text{ mm} < 5 mm ; IB: depth ≥ 5 mm \ge 5\text{ mm} ≥ 5 mm or clinically visible lesion confined to cervix).

Stage II : Extends beyond the cervix but not to the pelvic sidewall or lower third of the vagina (IIA: upper two-thirds of vagina; IIB: parametrial infiltration).

Stage III : Involves the lower third of the vagina (IIIA), extends to the pelvic sidewall or causes hydronephrosis (IIIB), or involves pelvic/para-aortic lymph nodes (IIIC).

Stage IV : Infiltrates the mucosa of the bladder or rectum (IVA) or extends to distant metastatic organs (IVB).

Therapeutic Principles

Early Stage (Stage IA1 without lymphovascular space invasion) : Conservative fertility-sparing cervical conization or simple hysterectomy.

Cervical treatment: Stage, size, nodes and fertility goals determine surgery versus chemoradiation. Selected early low-risk disease may have less radical surgery; do not apply radical hysterectomy to every early lesion.

Locally Advanced Disease (Stage IB3 to IVA) : Definitive concurrent chemoradiotherapy (external beam pelvic radiotherapy with concurrent weekly intravenous cisplatin , followed by high-dose-rate intracavitary brachytherapy ). Primary surgical resection is strictly contraindicated in locally advanced disease due to excessive morbidity and inferior overall survival compared to chemoradiotherapy.

Primary references (checked 7 October 2026): National cervical screening provider resources .